Brain tumor immunotherapy: seeing the brain in the body
► Tumor immunotherapy shows promise but many challenges remain, for all tumor sites. ► Delivery barriers, tumor plasticity, and the need for tumor antigens apply to all. ► Insight into the complexity of immune regulation is needed for all. ► For brain, immune privilege and the blood–brain barrier re...
Gespeichert in:
Veröffentlicht in: | Drug discovery today 2013-04, Vol.18 (7-8), p.399-406 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | ► Tumor immunotherapy shows promise but many challenges remain, for all tumor sites. ► Delivery barriers, tumor plasticity, and the need for tumor antigens apply to all. ► Insight into the complexity of immune regulation is needed for all. ► For brain, immune privilege and the blood–brain barrier receive great emphasis. ► Of equal value, brain shares principles, mediators and antigens with other sites.
Brain tumor immunotherapy is often interpreted in terms of immune privilege and the blood–brain barrier (BBB), but a broader view is warranted. The delicate regulatory balance of the immune system is relevant at any site, as are the heterogeneity and plasticity of tumor growth. Criteria for tumor antigens, and often the antigens themselves, cut across tumor types. Here, this broader view, complemented by current understanding of privilege and the BBB, provides the context for review. Future success is likely to exploit simplified methods, used in combination; and similarities – more than differences – between the brain and other sites. |
---|---|
ISSN: | 1359-6446 1878-5832 |
DOI: | 10.1016/j.drudis.2012.11.007 |